PUMA BIOTECHNOLOGY, INC. Accounts Receivable, Allowance for Credit Loss, Current
PUMA BIOTECHNOLOGY, INC. (PBYI) had Accounts Receivable, Allowance for Credit Loss, Current of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2026-02-26
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
- 2025-06-30: Accounts Receivable, Allowance for Credit Loss, Current $213.00K.
- 2025-03-31: Accounts Receivable, Allowance for Credit Loss, Current $575.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $213.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $575.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $362.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $760.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $808.00K 10-Q · filed 2024-08-01 |
| 2024-03-31 | $990.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $881.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $514.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $514.00K 10-Q · filed 2023-08-03 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-03 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.00M 10-K · filed 2022-03-03 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |